期刊文献+

罗格列酮诱导人肝癌HepG2细胞凋亡中p38MAPK通路的作用 被引量:6

p38MAPK Signaling Pathway in Rosiglitazone-induced Apoptosis of Hepatocellular Carcinoma Cell Line HepG2
在线阅读 下载PDF
导出
摘要 目的研究罗格列酮对人肝癌HepG2细胞增殖与凋亡的影响,探讨p38丝裂原活化蛋白激酶(p38MAPK)通路相关蛋白在其中发挥的作用。方法 MTT法检测罗格列酮对人肝癌HepG2细胞的增殖抑制率,流式细胞术检测细胞凋亡率,透射电子显微镜观察细胞凋亡形态变化,Western blot检测p38MAPK通路相关蛋白表达变化。结果罗格列酮可抑制HepG2细胞的增殖,诱导细胞凋亡(P<0.05);电子显微镜下可观察到典型的HepG2细胞凋亡表现。Western blot结果显示罗格列酮可激活p38MAPK通路,上调HepG2细胞中磷酸化p53及Bax蛋白的表达,下调Bcl-2蛋白的表达(P<0.05);而细胞外信号调节激酶ERK1/2的磷酸化程度没有明显改变。p38MAPK通路抑制剂SB203580可显著降低罗格列酮诱导的HepG2细胞的凋亡率;并且SB203580可部分逆转由罗格列酮引发的磷酸化p53、Bax及Bcl-2蛋白的表达变化。结论罗格列酮可通过激活p38MAPK通路诱导人肝癌HepG2细胞凋亡,其机制可能与p38MAPK通路参与磷酸化p53、Bax及Bcl-2蛋白的调控有关。 Objective To investigate the effects of Rosiglitazone(ROZ) on the proliferation and apoptosis of human hepatocellular carcinoma cell line HepG2 and to explore the role of p38MAPK signaling pathway in these processes. Methods HepG2 cell proliferation was determined by MTT method, and the apoptosis rates were measured by flow cytometry(FCM). The morphology of cell apoptosis was investigated by transmission electron microscopy(TEM). Western blot was performed to measure the protein expression related to p38MAPK signaling pathway. Result Rosiglitazone inhibited HepG2 cell proliferation in a concentration- and time-dependent manner(P<0.05), and the apoptosis rates were increased significantly(P<0.05). The typical morphological changes of apoptosis were chromatin condensation and aggregation at the periphery of nucleons and nuclear fragmentation. Rosiglitazone activated p-p38 MAPK pathway, upregulated the expression of p-p53 and Bax, and down-regulated Bcl-2 expression in HepG2 cells(P<0.05), while with no effect on ERK1/2 phosphorylation. The rosiglitazone-induced apoptosis of HepG2 cells and the changes of p-p53, Bcl-2 and Bax proteins were partly blocked by p38MAPK inhibitor SB203580. Conclusion Rosiglitazone could activate p38MAPK pathway by inhibiting HepG2 cell proliferation and inducing its apoptosis. The mechanism may be related with p38MAPK signaling pathway regulating the expression of p-p53, Bcl-2 and Bax proteins.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2014年第11期1181-1185,共5页 Cancer Research on Prevention and Treatment
基金 河北省高校强势特色学科项目[2005(52)] 河北省卫生厅资助课题(06142)
关键词 罗格列酮 P38丝裂原活化蛋白激酶 肝细胞癌 p53 Bcl-2 BAX Rosiglitazone p38MAPK Hepatocellular carcinoma p53 Bcl-2 Bax
  • 相关文献

参考文献9

  • 1Hang-Lung Chang,Chih-Yu Chen,Ya-Fen Hsu,Wen-Shin Kuo,George Ou,Pei-Ting Chiu,Yu-Han Huang,Ming-Jen Hsu.Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53- survivin signaling cascade[J].BBA - General Subjects.2013
  • 2Xiu Dong,Jian-Chun Li,Yuan-Yuan Jiang,Ming-Yu Xia,Shin-Ichi Tashiro,Satoshi Onodera,Takashi Ikejima.p38–NF-κB-promoted mitochondria-associated apoptosis and G2/M cell cycle arrest in norcantharidin-treated HeLa cells[J].Journal of Asian Natural Products Research.2012(11)
  • 3张萌,彭利,苗战军,徐卓,王顺祥,唐瑞峰,张凤瑞,王士杰.罗格列酮对肝癌SMMC-7721细胞VEGF蛋白表达的影响[J].肿瘤防治研究,2010,37(3):298-301. 被引量:6
  • 4Jia-Jun Liu,Xue-Jun Dai,Yan Xu,Pei-Qing Liu,Yong Zhang,Xiao-Dan Liu,Zhi-Gang Fang,Dong-Jun Lin,Ruo-Zhi Xiao,Ren-Wei Huang,He-Qing Huang.Inhibition of Lymphoma Cell Proliferation by Peroxisomal Proliferator-Activated Receptor-γ Ligands via Wnt Signaling Pathway[J].Cell Biochemistry and Biophysics.2012(1)
  • 5Peng Wang,Jinpu Yu,Qiang Yin,Wenliang Li,Xiubao Ren,Xishan Hao.Rosiglitazone Suppresses Glioma Cell Growth and Cell Cycle by Blocking the Transforming Growth Factor-Beta Mediated Pathway[J].Neurochemical Research.2012(10)
  • 6Megumi Fujita,Tatsurou Yagami,Miki Fujio,Chiaki Tohji,Kenkichi Takase,Yasuhiro Yamamoto,Kyoko Sawada,Motohiro Yamamori,Noboru Okamura.Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma[J].Cancer Letters.2011(2)
  • 7Ajaya Kumar Reka,Moloy T. Goswami,Rashmi Krishnapuram,Theodore J. Standiford,Venkateshwar G. Keshamouni.Molecular cross-regulation between PPAR-γ and other signaling pathways: Implications for lung cancer therapy[J].Lung Cancer.2011(2)
  • 8Wei-Ting Lee,Chia-Wen Chang.Bax is upregulated by p53 signal pathway in the SPE B-induced apoptosis[J].Molecular and Cellular Biochemistry (-).2010(1-2)
  • 9刘加军,刘文达,刘晓丹,Prem Raj-Shrestha,刘培庆,黄河清,吴传斌,王春芝,徐妍,肖若芝,林东军,黄仁魏.环格列酮通过PPARγ及P38 MAPK信号途径诱导白血病HL-60细胞凋亡[J].中华医学杂志,2010,90(32):2270-2274. 被引量:2

二级参考文献21

  • 1Weng JR, Chen CY, Pinzone JJ, et al. Beyond peroxisome proliferator-activated receptor gamma signaling; the multi-facets of the antitumor effect of thiazolidinediones[J]. Endocr Relat Cancer, 2006, 13(2):401-413.
  • 2Knapp P, Jarzabek K, Blachnio A, et al. The role of peroxisome proliferator-activated receptors (PPAR) in carcinogenesis [J]. Ginekol Pol, 2006 ,77(8) :643-651.
  • 3Panigrahy D, Singer S,Shen LQ, et al. PPARr ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis[J]. J Clin Invest, 2002, 110(7) : 923-932.
  • 4Xin X, Yang S, Kowalski J, et al. Peroxisome prolifer-atoractivated receptor gamma ligands are potent inhibitors of angiogenesis invitro and in vivo[J].J Biol Chem, 1999, 274 (13) :9116-9121.
  • 5Lindsley CW, Barnett SF, Layton ME, et al. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors[J]. Curr Cancer Drug Targets, 2008,8 ( 1 ) : 7-18,.
  • 6Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis [J]. Curr Cancer Drug Targets, 2008,8(1 ) : 19-26.
  • 7Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian earcinoma[J]. Clin Cancer Res, 2005, 11 (22): 8208-8212.
  • 8Farrow B, Evers BM. Activation of PPARgamma increases PTEN expression in pancreatic cancer cells[J].Biochem Biophys Res Commun, 2003,301 (1): 50-53.
  • 9Zoete V,Grosdidier A,Michielin O.Peroxisome proliferatoractivated receptor structures:ligand specificity,molecular switch and interactions with regulators.Biochim Biophys Acta,2007,1771:915-925.
  • 10Ulivieri C,Baldari CT.The potential of peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands in the treatment of hematological malignancies.Mini Rev Med Chem,2007,7:877-887.

共引文献6

同被引文献45

引证文献6

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部